Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, Herpel E, Jenzer M, Grüllich C, Jäger D, Sültmann H, Duensing A, Perner S, Cronauer MV, Stephan C, Debus J, Schrader AJ, Kristiansen G, Hohenfellner M, Duensing S.
Chen X, et al. Among authors: debus j.
Urol Oncol. 2018 Apr;36(4):161.e19-161.e30. doi: 10.1016/j.urolonc.2017.11.001. Epub 2017 Dec 1.
Urol Oncol. 2018.
PMID: 29198908